|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CCL13 |
 Gene summary |
| Basic gene Info. | Gene symbol | CCL13 |
| Gene name | chemokine (C-C motif) ligand 13 | |
| Synonyms | CKb10|MCP-4|NCC-1|NCC1|SCYA13|SCYL1 | |
| Cytomap | UCSC genome browser: 17q11.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_005408.2, | |
| Description | C-C motif chemokine 13CK-beta-10monocyte chemoattractant protein 4monocyte chemotactic protein 4new CC chemokine 1small inducible cytokine subfamily A (Cys-Cys), member 13small-inducible cytokine A13 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601391 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000181374 | ||
| HPRD : 03230 | ||
| Vega : OTTHUMG00000132890 | ||
| Protein | UniProt: Q99616 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CCL13 | |
| BioGPS: 6357 | ||
| Pathway | NCI Pathway Interaction Database: CCL13 | |
| KEGG: CCL13 | ||
| REACTOME: CCL13 | ||
| Pathway Commons: CCL13 | ||
| Context | iHOP: CCL13 | |
| ligand binding site mutation search in PubMed: CCL13 | ||
| UCL Cancer Institute: CCL13 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0007010 | cytoskeleton organization | 10072545 | GO:0008360 | regulation of cell shape | 10072545 | GO:0048245 | eosinophil chemotaxis | 10072545 |
| Top |
| Ligand binding site mutations for CCL13 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | T67 | T67N | BRCA | 1 | K68 | K68N | GBM | 1 | K71 | E72D | LUAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CCL13 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | K68 | K68N | -0.94516778 | K71 | E72D | -0.63957744 | T67 | T67N | -0.52822459 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CCL13 from PDB |
| Top |
| Differential gene expression and gene-gene network for CCL13 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CCL13 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CCL13 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CCL13 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of CCL13 |
| Multiple alignments for Q99616 in multiple species |
| LBS | AA sequence | # species | Species | K68 | VIFRTKLGKEI | 1 | Homo sapiens | K68 | VVFVTKLKREV | 1 | Mus musculus | K68 | VVFVTKLKREI | 1 | Rattus norvegicus | K71 | RTKLGKEICAD | 1 | Homo sapiens | K71 | VTKLKREVCAD | 1 | Mus musculus | K71 | VTKLKREICAD | 1 | Rattus norvegicus | L69 | IFRTKLGKEIC | 1 | Homo sapiens | L69 | VFVTKLKREVC | 1 | Mus musculus | L69 | VFVTKLKREIC | 1 | Rattus norvegicus | R47 | KISLQRLKSYV | 1 | Homo sapiens | R47 | MIPMSRLESYK | 1 | Mus musculus | R47 | MIPMSRLENYK | 1 | Rattus norvegicus | T67 | AVVFVTKLKRE | 2 | Mus musculus, Rattus norvegicus | T67 | AVIFRTKLGKE | 1 | Homo sapiens |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |